Genomic landscape and gene expression profiles of feline oral squamous cell carcinoma
暂无分享,去创建一个
Zachary L. Skidmore | Wesley C. Warren | O. Griffith | J. Grenier | Shirley Chu | J. Bryan | Andrew D. Miller | F. Ahmed | S. Peralta | Alana R. Rodney
[1] Chelsea K Martin,et al. Intersecting Mechanisms of Hypoxia and Prostaglandin E2-Mediated Inflammation in the Comparative Biology of Oral Squamous Cell Carcinoma , 2021, Frontiers in Oncology.
[2] E. Jonasch,et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] Xuan Liang,et al. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer , 2021, International journal of medical sciences.
[4] Lincy Jessica,et al. Molecular Mechanisms of Feline Cancers , 2020 .
[5] B. Cheng,et al. Epithelial‐to‐mesenchymal transition in oral squamous cell carcinoma: Challenges and opportunities , 2020, International journal of cancer.
[6] A. Klinakis,et al. TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection , 2020, EBioMedicine.
[7] B. Séguin,et al. Outcomes of Cats Treated with Maxillectomy: 60 Cases. A Veterinary Society of Surgical Oncology Retrospective Study. , 2020, Veterinary and comparative oncology.
[8] R. Fulton,et al. A domestic cat whole exome sequencing resource for trait discovery , 2020, Scientific Reports.
[9] J. R. Plaça,et al. Contributions of HOX genes to cancer hallmarks: Enrichment pathway analysis and review , 2020, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[10] A. Stenzinger,et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project , 2020, Journal for ImmunoTherapy of Cancer.
[11] R. O'Regan,et al. The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics , 2019, Cancer.
[12] J. Chang,et al. HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[13] N. Bacon,et al. Outcomes of eight cats with oral neoplasia treated with radical mandibulectomy. , 2019, Veterinary surgery : VS.
[14] Wei-Chung Cheng,et al. DriverDBv3: a multi-omics database for cancer driver gene research , 2019, Nucleic Acids Res..
[15] M. Kiupel,et al. Immunohistochemical Features of Epithelial-Mesenchymal Transition in Feline Oral Squamous Cell Carcinoma , 2019, Veterinary pathology.
[16] C. Garbe,et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study , 2019, Journal of Immunotherapy for Cancer.
[17] V. Budach,et al. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group. , 2019, European journal of cancer.
[18] S. Sabattini,et al. Prevalence of p53 dysregulations in feline oral squamous cell carcinoma and non-neoplastic oral mucosa , 2019, PloS one.
[19] Saman Maleki Vareki,et al. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors , 2018, Journal of Immunotherapy for Cancer.
[20] T. Dexheimer,et al. Investigation of novel chemotherapeutics for feline oral squamous cell carcinoma. , 2018 .
[21] Thomas Walker,et al. Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy , 2018, Scientific Reports.
[22] J. Hamilton. Targeting epithelial-to-mesenchymal transition (EMT) in feline oral squamous cell carcinoma (FOSCC) , 2018 .
[23] V. Mittal. Epithelial Mesenchymal Transition in Tumor Metastasis. , 2018, Annual review of pathology.
[24] Jing Wang,et al. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1 , 2017, Oncogene.
[25] K. Ge,et al. Histone H3 lysine 4 methyltransferase KMT2D. , 2017, Gene.
[26] J. Grandis,et al. EGFR-targeted therapies in the post-genomic era , 2017, Cancer and Metastasis Reviews.
[27] K. Matsuo,et al. Alcohol and head and neck cancer , 2017, Cancer and Metastasis Reviews.
[28] Moriah H Nissan,et al. OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.
[29] K. Lamb,et al. Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma , 2017, Journal of feline medicine and surgery.
[30] Jeffrey N Myers,et al. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response , 2016, Journal of cellular biochemistry.
[31] P. Gönczy,et al. KAT2A/KAT2B-targeted acetylome reveals a role for PLK4 acetylation in preventing centrosome amplification , 2016, Nature Communications.
[32] Yang Sun,et al. Transcriptomic characterization of differential gene expression in oral squamous cell carcinoma: a meta-analysis of publicly available microarray data sets , 2016, Tumor Biology.
[33] Shu-Chun Lin,et al. miR-31 targets ARID1A and enhances the oncogenicity and stemness of head and neck squamous cell carcinoma , 2016, Oncotarget.
[34] R. Shaw,et al. Aetiology and risk factors for head and neck cancer: United Kingdom National Multidisciplinary Guidelines , 2016, The Journal of Laryngology & Otology.
[35] R. Morgan,et al. The role of HOX genes in head and neck squamous cell carcinoma. , 2016, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[36] T. Rosol,et al. Animal models of head and neck squamous cell carcinoma. , 2016, Veterinary journal.
[37] G. Kristiansen,et al. Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types , 2016, Oncotarget.
[38] F. Cunningham,et al. The Ensembl Variant Effect Predictor , 2016, bioRxiv.
[39] J. Mesirov,et al. The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .
[40] Marie-Agnès Dillies,et al. SARTools: A DESeq2- and EdgeR-Based R Pipeline for Comprehensive Differential Analysis of RNA-Seq Data , 2015, bioRxiv.
[41] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[42] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[43] Melissa D. Sánchez,et al. Feline Oral Squamous Cell Carcinoma: Clinical Manifestations and Literature Review , 2015, Journal of veterinary dentistry.
[44] Steven J. M. Jones,et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.
[45] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[46] R. Gibbs,et al. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types , 2014, The Journal of pathology.
[47] Michael F. Ochs,et al. Activation of the NOTCH pathway in head and neck cancer. , 2014, Cancer research.
[48] J. Wypij. A Naturally Occurring Feline Model of Head and Neck Squamous Cell Carcinoma , 2013, Pathology research international.
[49] R. Schneider,et al. Cancers with wrong HATs: the impact of acetylation. , 2013, Briefings in functional genomics.
[50] Tian-Li Wang,et al. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. , 2011, Cancer research.
[51] D. Argyle,et al. Expression of epidermal growth factor receptor (EGFR) and Ki67 in feline oral squamous cell carcinomas (FOSCC). , 2011, Veterinary and comparative oncology.
[52] Marcel Martin. Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .
[53] T. Rosol,et al. Bone-Invasive Oral Squamous Cell Carcinoma in Cats , 2011, Veterinary pathology.
[54] L. Marconato,et al. Epidermal growth factor receptor expression is predictive of poor prognosis in feline cutaneous squamous cell carcinoma , 2010, Journal of feline medicine and surgery.
[55] C. Ragin,et al. The Epidemiology and Risk Factors of Head and Neck Cancer: a Focus on Human Papillomavirus , 2007, Journal of dental research.
[56] T. Rosol,et al. Feline head and neck squamous cell carcinoma: a natural model for the human disease and development of a mouse model. , 2006, Veterinary and comparative oncology.
[57] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[58] M. Dooner,et al. p53 Expression and Environmental Tobacco Smoke Exposure in Feline Oral Squamous Cell Carcinoma , 2004, Veterinary pathology.
[59] A. Moore,et al. Environmental and lifestyle risk factors for oral squamous cell carcinoma in domestic cats. , 2003, Journal of veterinary internal medicine.
[60] C. Perisanidis. Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review. , 2017, In vivo.
[61] J. Coppee,et al. SARTools : a DESeq 2-and edgeR-based R pipeline for comprehensive differential analysis of RNA-Seq data , 2015 .
[62] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[63] Claude-Alain H. Roten,et al. Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..
[64] P. Hainaut,et al. TP53: a key gene in human cancer. , 2002, Biochimie.
[65] G. Staal,et al. The inhibitory effect of deoxyadenosine and deoxyguanosine on in vitro lymphocyte function are expressed at different stages of lymphocyte activation. , 1986 .